← Eichor
Study identifier: NCT07722884 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Tamsulosin Monotherapy Versus Combination Therapy With Tadalafil (2.5 mg vs 5 mg) in Managing Male LUTS Secondary to BPH

Condition: Safety · Efficacy · Tamsulosin  ·  Sponsor: Ain Shams University

PhaseNA
Planned participants90
Who can joinAll sexes, 45 Years to no upper limit
Healthy volunteersNo

About this study

This study aims to evaluate the short-term impact and clinical outcomes of tamsulosin monotherapy versus combination therapy with tamsulosin plus tadalafil (2.5 mg vs. 5 mg) on lower urinary tract symptoms (LUTS) severity and patient quality of life in men with benign prostatic hyperplasia (BPH). It also seeks to determine whether the lower tadalafil dose provides adequate symptom relief while minimizing adverse effects over a 12-week follow-up period.

This description comes directly from the study's public registry record.

Talk to the study team

Salah N Salem, MBBCH  ·  00201066047555  ·  salahsalem@med.asu.edu.eg

Always discuss trial participation with your own doctor first.

Locations (1)

Ain Shams UniversityCairo, Cairo Governorate, EgyptRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07722884